A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• A participant assigned female at birth is eligible to participate if not pregnant orbreastfeeding, is not a participant of childbearing potential (POCBP), or is a POCBPand agrees to follow contraceptive guidance during the study intervention period andfor at least 35 days after the last dose of study intervention.

• For participants with moderate or severe hepatic impairment: Have a diagnosis ofchronic (>6 months), stable, hepatic impairment with features of cirrhosis due toany etiology (stability of hepatic disease should correspond to no acute episodes ofillness within the previous 2 months due to deterioration in hepatic function).

Exclusion Criteria:

• History of cancer (malignancy).

• Had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL)within 4 weeks prior to the prestudy (screening) visit.

• Participants with moderate or severe hepatic impairment who are positive for humanimmunodeficiency virus (HIV)-1 or HIV-2 at the prestudy (screening) visit.

• Participants with moderate or severe hepatic impairment who received antiviraland/or immune modulating therapy for hepatitis B virus (HBV) or hepatitis C virus (HCV) within 90 days prior to study start.

• Healthy participants who are unable to refrain from or anticipate the use of anymedication, including prescription and nonprescription drugs or herbal remediesbeginning approximately 2 weeks (or 5 half-lives) prior to administration of theinitial dose of study intervention, throughout the study (including washoutintervals between treatment periods), until the poststudy visit.